Prospects not looking good yet The number of people who were tested for SARS-CoV-2 increased by 20% last week. The number of people who tested positive rose by 7%. The reproduction number also rose above 1.
Care workers in nursing homes and small-scale residential facilities invited for COVID-19 vaccination starting today As of today, the ca. 269,000 care workers of nursing homes and small-scale residential facilities in the Netherlands are invited to make an appointment for a COVID-19 vaccination.
COVID-19 consequences impact vulnerable groups more in the long term The effects of the corona crisis have a greater impact on vulnerable groups in society, such as lower-educated adults, young people, the elderly and people with underlying health problems.
Spread of tick-borne encephalitis virus in the Netherlands Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Rubber granulate on synthetic turf fields causes environmental impact Use of rubber granulate sourced from car tyres, on synthetic turf fields can be harmful to the environment in the close vicinity of these fields.
First products Dutch Public Health Foresight study available in English In 2017, RIVM launched a Trend Scenario, as well as three thematic reports about the future demand for health care, technology and wider determinants of health.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Trend scenario PHF- 2018 identifies societal challenges for the future If historical trends continue unchanged, dementia will be the leading cause of disease burden in 2040 and the main cause of death.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.